TY - JOUR
T1 - Rhenium tricarbonyl core complexes with ligands derived from arylpiperazines
AU - Wei, Lihui
AU - Banerjee, Sangeeta Ray
AU - Levadala, Murali K.
AU - Babich, John
AU - Zubieta, Jon
N1 - Funding Information:
This work was supported by a grant from the Department of Energy (DOE), Office of Health and Environmental Research D2-FG02-99ER62791.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - The reactions of potentially tridentate ligands, derived from N-arylpiperazines, with [NEt4]2[Re(CO)3Br3] have been investigated. The compounds [Re(CO)3{NC5H4CH2N(H) CH2CH2-Fphenpip}]Br (1Br), [Re(CO)3{(NC5H4CH2)2 NCH2CH2CH2-CH3 OphenpipH}]Br2·2CH2Cl2· H2O (2Br2·2CH2Cl2·H2O) and [Re(CO)3{(CH3N2C3H2 CH2)(O2CCH2)N(CH2)3- CH3OphenpipH2}]BrCl·1.5MeOH· H2O(3BrCl·1.5MeOH·H2O) have been prepared and structurally characterized. The compounds exhibitfac[Re(CO)3N3] or fac-[Re(CO)3N2O] coordination geometry in the cationic molecular units. Both compounds are chemically robust and survive histidine and cysteine challenges with greater than 95% recovery. Crystal data for C21H23BrFN4O3Re (1Br): monoclinic P21/c, a = 11.344(1) Å, b = 14.433(1)Å, c= 13.730(1) Å, β = 103.092(2)°, V = 2189.5(2) Å3, z = 4; C31H41Br2Cl4N5 O5Re (2Br2·2CH2Cl2· H2O): monoclinic P21/c, a = 30.015(1) Å, b = 8.9324(4) Å, c = 14.73610(6) Å, β = 103.195 (1)°, V = 3846.5(3) Å3, Z = 4; C25.5H39BrClN5O8.5Re (3BrCl·1.5MeOH·H2O): triclinic P1, a = 11.818(2) Å, b = 13.292(2) A, c = 14.517(2) A, α = 63.915(2)°, β = 66-373(2)°, γ = 67.416(2)° V = 1815.6(4) Å3, Z = 2.
AB - The reactions of potentially tridentate ligands, derived from N-arylpiperazines, with [NEt4]2[Re(CO)3Br3] have been investigated. The compounds [Re(CO)3{NC5H4CH2N(H) CH2CH2-Fphenpip}]Br (1Br), [Re(CO)3{(NC5H4CH2)2 NCH2CH2CH2-CH3 OphenpipH}]Br2·2CH2Cl2· H2O (2Br2·2CH2Cl2·H2O) and [Re(CO)3{(CH3N2C3H2 CH2)(O2CCH2)N(CH2)3- CH3OphenpipH2}]BrCl·1.5MeOH· H2O(3BrCl·1.5MeOH·H2O) have been prepared and structurally characterized. The compounds exhibitfac[Re(CO)3N3] or fac-[Re(CO)3N2O] coordination geometry in the cationic molecular units. Both compounds are chemically robust and survive histidine and cysteine challenges with greater than 95% recovery. Crystal data for C21H23BrFN4O3Re (1Br): monoclinic P21/c, a = 11.344(1) Å, b = 14.433(1)Å, c= 13.730(1) Å, β = 103.092(2)°, V = 2189.5(2) Å3, z = 4; C31H41Br2Cl4N5 O5Re (2Br2·2CH2Cl2· H2O): monoclinic P21/c, a = 30.015(1) Å, b = 8.9324(4) Å, c = 14.73610(6) Å, β = 103.195 (1)°, V = 3846.5(3) Å3, Z = 4; C25.5H39BrClN5O8.5Re (3BrCl·1.5MeOH·H2O): triclinic P1, a = 11.818(2) Å, b = 13.292(2) A, c = 14.517(2) A, α = 63.915(2)°, β = 66-373(2)°, γ = 67.416(2)° V = 1815.6(4) Å3, Z = 2.
KW - N-arylpiperazine derivatives
KW - Radiopharmaceuticals
KW - {Re(CO)} core
UR - http://www.scopus.com/inward/record.url?scp=0041743807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041743807&partnerID=8YFLogxK
U2 - 10.1016/S1387-7003(03)00176-X
DO - 10.1016/S1387-7003(03)00176-X
M3 - Article
AN - SCOPUS:0041743807
VL - 6
SP - 1099
EP - 1103
JO - Inorganic Chemistry Communication
JF - Inorganic Chemistry Communication
SN - 1387-7003
IS - 8
ER -